Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery

被引:82
作者
Chahal, Parminder Singh [1 ]
Schulze, Erica [1 ]
Tran, Rosa [1 ]
Montes, Johnny [1 ]
Kamen, Amine A. [1 ]
机构
[1] Natl Res Council Canada, Vaccine Program, Montreal, PQ H4P 2R2, Canada
关键词
Gene therapy; Large-scale transient transfection; Process; Bioreactor; Manufacturing; Production; SERUM-FREE PRODUCTION; VIRAL VECTORS; HIGH-TITER; SODIUM-BUTYRATE; NEUTRALIZING ANTIBODIES; CONGENITAL AMAUROSIS; SCALABLE PRODUCTION; IMMUNE-RESPONSES; SKELETAL-MUSCLE; CYSTIC-FIBROSIS;
D O I
10.1016/j.jviromet.2013.10.038
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Adeno-associated virus (AAV) is being used successfully in gene therapy. Different serotypes of AAV target specific organs and tissues with high efficiency. There exists an increasing demand to manufacture various AAV serotypes in large quantities for pre-clinical and clinical trials. A generic and scalable method has been described in this study to efficiently produce AAV serotypes (AAV1-9) by transfection of a fully characterized cGMP HEK293SF cell line grown in suspension and serum-free medium. First, the production parameters were evaluated using AAV2 as a model serotype. Second, all nine AAV serotypes were produced successfully with yields of 10(13) Vg/L cell culture. Subsequently, AAV2 and AAV6 serotypes were produced in 3-L controlled bioreactors where productions yielded up to 10(13) Vg/L similar to the yields obtained in shake-flasks. For example, for AAV2 10(13) Vg/L cell culture (6.8 x 10(11) IVP/L) were measured between 48 and 64 h post transfection (hpt). During this period, the average cell specific AAV2 yields of 6800 Vg per cell and 460 IVP per cell were obtained with a Vg to IVP ratio of less than 20. Successful operations in bioreactors demonstrated the potential for scale-up and industrialization of this generic process for manufacturing AAV serotypes efficiently. Crown Copyright (C) 2013 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 85 条
[1]   Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures [J].
Ansorge, Sven ;
Lanthier, Stephane ;
Transfiguracion, Julia ;
Durocher, Yves ;
Henry, Olivier ;
Kamen, Amine .
JOURNAL OF GENE MEDICINE, 2009, 11 (10) :868-876
[2]   The AAV Vector Toolkit: Poised at the Clinical Crossroads [J].
Asokan, Aravind ;
Schaffer, David V. ;
Samulski, R. Jude .
MOLECULAR THERAPY, 2012, 20 (04) :699-708
[3]   Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle [J].
Asokan, Aravind ;
Conway, Julia C. ;
Phillips, Jana L. ;
Li, Chengwen ;
Hegge, Julia ;
Sinnott, Rebecca ;
Yadav, Swati ;
DiPrimio, Nina ;
Nam, Hyun-Joo ;
Agbandje-McKenna, Mavis ;
McPhee, Scott ;
Wolff, Jon ;
Samulski, R. Jude .
NATURE BIOTECHNOLOGY, 2010, 28 (01) :79-U107
[4]   Critical assessment of current adeno-associated viral vector production and quantification methods [J].
Aucoin, Marc G. ;
Perrier, Michel ;
Kamen, Amine A. .
BIOTECHNOLOGY ADVANCES, 2008, 26 (01) :73-88
[5]   Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures [J].
Backliwal, Gaurav ;
Hildinger, Markus ;
Kuettel, Ivan ;
Delegrange, Fanny ;
Hacker, David L. ;
Wurm, Florian M. .
BIOTECHNOLOGY AND BIOENGINEERING, 2008, 101 (01) :182-189
[6]   Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat [J].
Bish, Lawrence T. ;
Morine, Kevin ;
Sleeper, Meg M. ;
Sanmiguel, Julio ;
Wu, Di ;
Gao, Guangping ;
Wilson, James M. ;
Sweeney, H. Lee .
HUMAN GENE THERAPY, 2008, 19 (12) :1359-1368
[7]   Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors [J].
Boutin, Sylvie ;
Monteilhet, Virginie ;
Veron, Philippe ;
Leborgne, Christian ;
Benveniste, Olivier ;
Montus, Marie Francoise ;
Masurier, Carole .
HUMAN GENE THERAPY, 2010, 21 (06) :704-712
[8]   Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system [J].
Burger, C ;
Gorbatyuk, OS ;
Velardo, MJ ;
Peden, CS ;
Williams, P ;
Zolotukhin, S ;
Reier, PJ ;
Mandel, RJ ;
Muzyczka, N .
MOLECULAR THERAPY, 2004, 10 (02) :302-317
[9]   Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery [J].
Chadeuf, G ;
Ciron, C ;
Moullier, P ;
Salvetti, A .
MOLECULAR THERAPY, 2005, 12 (04) :744-753
[10]  
Chadeuf G, 2000, J GENE MED, V2, P260